OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Author:
Funder
AstraZeneca
AstraZeneca and Merck & Co.
Inc.
NIH/NCI Cancer Center
Breast Cancer Research Foundation
Mudskipper Business Ltd
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz012/28408683/mdz012.pdf
Reference7 articles.
1. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years;Malone;Cancer Res,2006
2. Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry;Kurian;Cancer Epidemiol Biomarkers Prev,2009
3. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer;Couch;J Clin Oncol,2015
4. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation;Robson;N Engl J Med,2017
5. Can contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit?;Kummel;Ann Oncol,2017
Cited by 478 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Small molecule agents for triple negative breast cancer: Current status and future prospects;Translational Oncology;2024-03
2. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial;European Journal of Cancer;2024-03
3. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial;The Lancet Oncology;2024-02
4. The Current and Future Roles of Precision Oncology in Advanced Breast Cancer;Journal of Nuclear Medicine;2024-02-01
5. Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs);Cancer Treatment Reviews;2024-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3